Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

• Published in: Cancer cell international Vol. 24; no. 1; p. 133
• Main Authors: Chen, Tong, Wang, Mingzhao, Chen, Yanchao, Liu, Yutao
• Format: Journal Article
• Language: English
• Published: England BioMed Central 15.04.2024; BMC
• Subjects: Antigen; Antigens; Cancer; CAR T cell therapy; Cell death; Cell therapy; Chimeric antigen receptors; Clinical trials; Cytokines; Design; Epidermal growth factor; Glioma; Heterogeneity; Immunotherapy; Lymphocytes; Lymphocytes T; Malignancy; Proteins; Review; Signal transduction; Solid tumor; Solid tumors; T cell exhaustion; Toxicity; Tumor microenvironment; Tumors; Antigen; Heterogeneity; Solid tumor; Tumor microenvironment; Toxicity; Combined therapies; T cell exhaustion; Clinical trial; CAR T cell therapy
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-024-03315-3

The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough. Nevertheless, the utilization and effectiveness of CAR-T cell therapy in solid tumors are still limited primarily because of the absence of tumor-specific target antigen, the existence of immunosuppressive tumor microenvironment, restricted T cell invasion and proliferation, and the occurrence of severe toxicity. This review explored the history of CAR-T and its latest advancements in the management of solid tumors. According to recent studies, optimizing the design of CAR-T cells, implementing logic-gated CAR-T cells and refining the delivery methods of therapeutic agents can all enhance the efficacy of CAR-T cell therapy. Furthermore, combination therapy shows promise as a way to improve the effectiveness of CAR-T cell therapy. At present, numerous clinical trials involving CAR-T cells for solid tumors are actively in progress. In conclusion, CAR-T cell therapy has both potential and challenges when it comes to treating solid tumors. As CAR-T cell therapy continues to evolve, further innovations will be devised to surmount the challenges associated with this treatment modality, ultimately leading to enhanced therapeutic response for patients suffered solid tumors.